What is Lexaria Bioscience Corp's earnings per share (EPS)?

Lexaria Bioscience Corp (LEXX) reported diluted earnings per share of -$0.66 for fiscal year 2025. This represents a -40.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lexaria Bioscience Corp (LEXX) Financials

LEXX

Trailing 12 months to May 31, 2026

Revenue $194K -68.5% YoY

Net Income -$7.7M +32.1% YoY

EPS (Diluted) -$0.34 +49.3% YoY

Free Cash Flow -$7.5M +23.6% YoY

Market Cap $8.5M as of Sep 10, 2026

Price / Sales 44.0x on $194K revenue, trailing 12 months to May 31, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to May 31, 2026

Price / Book 1.8x on $4.7M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended May 31, 2026 Reported Jul 13, 2026 Currency USD FYE August

Newest figures come from the 10-Q for Q3 FY2026, filed Jul 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LEXX SEC filings page.

Lexaria Bioscience Corp (LEXX) reported $194K in revenue over the twelve months to May 31, 2026, down 68.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LEXX FY2025 2026-08-30

Development-stage spending is Lexaria’s dominant mechanic, expanding far faster than its small commercial revenue base.

R&D intensity more than tripled to $8.2M in FY2025 from $2.4M in FY2024, while revenue remained below $1M; the business is funding development rather than benefiting from operating scale. Cash conversion was direct: operating cash flow was -$10.5M versus net loss of -$11.9M, indicating that reported losses largely translated into cash use rather than mainly non-cash charges.

FY2025 gross margin reached 99.6%, with cost of revenue of only $3K; the economic bottleneck sits below gross profit. R&D and SG&A totaled $12.6M, explaining why a high product-level margin still produced a substantial operating loss.

Balance-sheet flexibility narrowed: debt-to-equity rose from 0.2x in FY2024 to 0.5x in FY2025, indicating greater reliance on liabilities relative to equity. The current ratio fell from 7.2x to 2.3x, while reported liquidity measured 2.6 months of annual operating outflow at FY2025 year-end.

Financial Health Signals

Financial health score not available

Lexaria Bioscience Corp does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-26.68

Lexaria Bioscience Corp scores -26.68, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.5M) relative to total liabilities ($1.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Lexaria Bioscience Corp passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Lexaria Bioscience Corp reported a net loss of $11.9M while operations used $10.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

QoQ-100.0%

Lexaria Bioscience Corp generated $0 in revenue in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

EBITDA

-$2.0M

YoY+46.8%

QoQ-37.7%

Lexaria Bioscience Corp's EBITDA was -$2.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.8% from the same quarter a year earlier. Against the prior quarter it is down 37.7%.

Net Income

-$2.0M

YoY+47.4%

QoQ-37.3%

Lexaria Bioscience Corp reported -$2.0M in net income in Q3 2026. This represents an increase of 47.4% from the same quarter a year earlier. Against the prior quarter it is down 37.3%.

EPS (Diluted)

-$0.08

YoY+61.9%

QoQ-33.3%

Lexaria Bioscience Corp earned -$0.08 per diluted share (EPS) in Q3 2026. This represents an increase of 61.9% from the same quarter a year earlier. Against the prior quarter it is down 33.3%.

Cash & Balance Sheet

Free Cash Flow

-$1.6M

YoY+54.4%

QoQ+25.8%

Lexaria Bioscience Corp recorded an outflow of $1.6M in free cash flow in Q3 2026, representing a cash shortfall after capex. This represents an increase of 54.4% from the same quarter a year earlier. Against the prior quarter it is up 25.8%.

Cash & Debt

$3.5M

YoY-23.9%

QoQ-31.4%

5Y CAGR-15.5%

10Y CAGR+57.6%

Lexaria Bioscience Corp held $3.5M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

25M

YoY+26.7%

QoQ0.0%

Lexaria Bioscience Corp had 25M shares outstanding in Q3 2026. This represents an increase of 26.7% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity

-42.0%

YoY+26.2pp

QoQ-20.1pp

5Y CAGR-17.0pp

10Y CAGR+171.8pp

Lexaria Bioscience Corp's ROE was -42.0% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is up 26.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.1 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending

$971K

YoY-64.3%

QoQ+104.2%

5Y CAGR+16.4%

10Y CAGR+139.2%

Lexaria Bioscience Corp invested $971K in research and development in Q3 2026. This represents a decrease of 64.3% from the same quarter a year earlier. Against the prior quarter it is up 104.2%.

Capital Expenditures

YoY-100.0%

QoQ-100.0%

Lexaria Bioscience Corp reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q3 2026.

LEXX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LEXX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$194K	$706K+52.0%	$464K+105.2%	$226K-11.4%	$255K-64.7%	$723K+129.6%	$315K+41.4%	$223K-48.6%	$433K+580.9%	$64K+56.3%	$41K+177.0%	$15K	$0	N/A	N/A	N/A
Cost of Revenue	$0	$3K-43.6%	$5K-84.7%	$32K-56.2%	$72K-59.0%	$175K+76.4%	$99K+334.1%	$23K-9.1%	$25K-15.3%	$30K-34.8%	$46K+52.6%	$30K	$0-100.0%	$795K+1.5%	$783K+17.3%	$668K
Gross Profit	$194K	$703K+53.1%	$459K+136.0%	$195K+6.1%	$184K-66.5%	$547K+154.1%	$215K+7.9%	$200K-51.1%	$408K+1104.2%	$34K+792.0%	-$5K+67.7%	-$15K	$0-100.0%	$302K-47.4%	$574K+23.3%	$466K
R&D Expenses	$4.0M	$8.2M+249.0%	$2.4M-35.6%	$3.7M+99.0%	$1.8M+45.9%	$1.3M+226.3%	$387K-30.3%	$556K+12.8%	$493K+809.6%	$54K+500.5%	$9K-93.8%	$146K	$0	N/A	N/A	N/A
SG&A Expenses	$3.9M	$4.3M+12.8%	$3.9M+25.8%	$3.1M-38.3%	$5.0M-0.2%	$5.0M+25.0%	$4.0M+1238.2%	$297K+36.6%	$218K+67.8%	$130K-3.0%	$134K+609.8%	$19K+62.0%	$12K+72.1%	$7K+127.7%	$3K-42.8%	$5K
Operating Income	-$7.7M	-$11.9M-106.5%	-$5.8M+12.0%	-$6.5M+1.3%	-$6.6M-16.4%	-$5.7M	N/A	N/A	N/A	N/A	-$1.3M+35.6%	-$2.0M-27.2%	-$1.6M	N/A	N/A	N/A
EBITDA	N/A	-$11.8M-107.1%	-$5.7M+10.6%	-$6.4M+2.0%	-$6.5M-16.9%	-$5.6M	N/A	N/A	N/A	N/A	-$1.3M+35.6%	-$2.0M	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	$8K	$0	N/A	N/A	N/A	N/A	N/A	$6K+167.3%	$2K-92.9%	$32K-81.0%	$166K-38.0%	$267K+12.5%	$238K+6.2%	$224K
Income Tax	N/A	N/A	N/A	N/A	$0-100.0%	$6K+162.7%	$2K-86.9%	$18K	$0	$0	$0	N/A	N/A	N/A	N/A	N/A
Net Income	-$7.7M	-$11.9M-105.4%	-$5.8M+13.0%	-$6.7M+8.3%	-$7.3M-80.5%	-$4.0M+1.4%	-$4.1M-199.6%	$4.1M-37.9%	$6.6M+442.1%	-$1.9M-51.1%	-$1.3M+35.6%	-$2.0M-27.2%	-$1.6M	N/A	N/A	-$538K
EPS (Diluted)	-$0.34	-$0.66-40.4%	-$0.47	-$1.01	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.04
Diluted Shares (Avg)	N/A	18M+45.3%	12M	7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	14M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Revenue	$0-100.0%	$20K-88.5%	$0-100.0%	$174K+107.1%	$174K+107.1%	$174K+20.0%	$184K+21.6%	$84K+173.3%
Cost of Revenue	$0	$0	$0-100.0%	$0	$0	$0	$3K-43.6%	$0
Gross Profit	$0-100.0%	$20K-88.5%	$0-100.0%	$174K+107.1%	$174K+107.1%	$174K+20.0%	$181K+23.7%	$84K+173.3%
R&D Expenses	$971K-64.3%	$475K-71.8%	$671K-65.6%	$1.9M+94.6%	$2.7M+374.2%	$1.7M+585.9%	$2.0M+240.0%	$967K+93.3%
SG&A Expenses	$1.0M-15.2%	$997K-19.6%	$902K-1.8%	$980K-25.7%	$1.2M-3.7%	$1.2M+118.4%	$919K+29.2%	$1.3M+104.8%
Operating Income	-$2.0M+46.8%	-$1.5M+47.2%	-$1.6M+41.5%	-$2.7M-22.0%	-$3.8M-115.2%	-$2.8M-311.8%	-$2.7M-136.2%	-$2.2M-97.7%
EBITDA	-$2.0M+46.8%	-$1.4M	-$1.6M+41.8%	N/A	-$3.7M-115.3%	N/A	-$2.7M-141.5%	-$2.2M-112.8%
Income Tax	$14	$3K	$2K	N/A	$0	$0	$0	N/A
Net Income	-$2.0M+47.4%	-$1.4M+46.6%	-$1.6M+41.0%	-$2.7M-23.4%	-$3.8M-112.7%	-$2.7M-317.7%	-$2.7M-129.3%	-$2.2M-76.3%
EPS (Diluted)	-$0.08+61.9%	-$0.06+60.0%	-$0.07+56.3%	-$0.13+13.3%	-$0.21-61.5%	-$0.15	-$0.16	-$0.15
Diluted Shares (Avg)	25M+35.6%	24M+39.6%	21M+28.2%	N/A	18M+32.1%	18M	17M	N/A

Not reported in any period shown, so not listed: Interest Expense, EPS (Basic).

LEXX Balance Sheet

LEXX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$4.2M-52.9%	$8.9M+187.5%	$3.1M-60.6%	$7.8M-41.0%	$13.3M+369.1%	$2.8M+5.7%	$2.7M+10.0%	$2.4M-15.0%	$2.9M+404.8%	$567K-20.4%	$712K-73.0%	$2.6M-26.3%	$3.6M-14.8%	$4.2M-3.4%	$4.3M
Current Assets	$3.5M-56.1%	$7.9M+267.1%	$2.2M-69.2%	$7.0M-43.9%	$12.4M+546.1%	$1.9M+5.9%	$1.8M-20.4%	$2.3M-18.3%	$2.8M+448.0%	$510K-24.4%	$675K-73.7%	$2.6M+1655.3%	$146K-69.1%	$473K+79.0%	$264K
Cash & Equivalents	$1.8M-72.3%	$6.5M+380.7%	$1.4M-76.7%	$5.8M-46.8%	$10.9M+743.9%	$1.3M+0.7%	$1.3M-25.6%	$1.7M-31.8%	$2.5M+2612.1%	$93K-64.1%	$260K-63.0%	$703K+972.6%	$66K-63.7%	$181K+478.6%	$31K
Short-Term Investments	$143K+156.7%	$56K-55.6%	$126K-63.8%	$347K-58.3%	$834K+4215.7%	$19K-69.9%	$64K+532.6%	$10K	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	$0-100.0%	$38K+29.6%	$30K-74.6%	$117K-8.3%	$127K+46.0%	$87K+29.9%	$67K-50.1%	$135K-19.8%	$168K	$0	N/A	N/A	N/A
Accounts Receivable	$368K+138.5%	$154K+21.9%	$127K-37.2%	$202K-41.1%	$342K+9.1%	$314K+14.9%	$273K+2.8%	$266K+486.7%	$45K-65.4%	$131K+317.7%	$31K-67.6%	$97K+22.5%	$79K-72.8%	$291K+26.0%	$231K
Long-Term Investments	$349K+2384.7%	$14K0.0%	$14K	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$68K	$0	$0	$0
Total Liabilities	$1.6M+30.1%	$1.2M+199.3%	$404K+100.5%	$201K-0.9%	$203K-41.2%	$346K+87.5%	$185K+322.8%	$44K-52.7%	$92K-69.3%	$301K+445.3%	$55K-94.0%	$918K-37.7%	$1.5M-16.7%	$1.8M+5.5%	$1.7M
Current Liabilities	$1.5M+35.8%	$1.1M+310.6%	$268K+38.0%	$194K+26.6%	$153K-32.2%	$226K+22.4%	$185K+322.8%	$44K-52.7%	$92K	N/A	$55K-94.0%	$918K-35.1%	$1.4M-17.3%	$1.7M+58.7%	$1.1M
Non-Current Liabilities	$79K-27.8%	$109K-19.7%	$136K+1739.9%	$7K-85.2%	$50K-58.4%	$120K	$0	$0	$0+100.0%	-$133K	$0	$0-100.0%	$59K0.0%	$59K-90.1%	$599K
Total Equity	$3.0M-62.8%	$8.0M+164.0%	$3.0M-61.7%	$7.9M-39.2%	$13.1M+426.3%	$2.5M-0.3%	$2.5M+4.3%	$2.4M-13.7%	$2.8M+940.4%	$266K-65.6%	$772K-55.0%	$1.7M-18.2%	$2.1M-13.3%	$2.4M-9.0%	$2.7M
Retained Earnings	-$63.5M-23.1%	-$51.6M-12.7%	-$45.8M-17.0%	-$39.1M-22.8%	-$31.8M-14.5%	-$27.8M-16.5%	-$23.9M-20.7%	-$19.8M-50.1%	-$13.2M-16.5%	-$11.3M-12.0%	-$10.1M-21.3%	-$8.3M-64.4%	-$5.1M-7.3%	-$4.7M-5.6%	-$4.5M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$4.8M-29.1%	$6.5M-25.2%	$6.1M-38.2%	$4.2M-52.9%	$6.7M-32.7%	$8.7M+36.6%	$9.8M+170.0%	$8.9M+187.5%
Current Assets	$4.1M-30.0%	$5.8M-25.3%	$5.4M-39.2%	$3.5M-56.1%	$5.8M-36.1%	$7.7M+42.6%	$8.8M+227.7%	$7.9M+267.1%
Cash & Equivalents	$3.5M-23.9%	$5.1M-21.5%	$4.3M-46.8%	$1.8M-72.3%	$4.6M-45.6%	$6.5M+38.1%	$8.1M+313.4%	$6.5M+380.7%
Short-Term Investments	$142K+323.7%	$141K+91.1%	$143K+259.3%	$143K+156.7%	$34K-27.6%	$74K-15.7%	$40K-44.9%	$56K-55.6%
Accounts Receivable	$49K-86.3%	$42K-87.3%	$88K-66.6%	$368K+138.5%	$358K+71.8%	$331K-7.3%	$263K-50.7%	$154K+21.9%
Long-Term Investments	$0	$0	$0	$349K+2384.7%	$0	$0	$0	$14K0.0%
Total Liabilities	$437K-72.2%	$277K-85.5%	$1.5M+282.1%	$1.6M+30.1%	$1.6M+480.3%	$1.9M+838.7%	$400K+57.3%	$1.2M+199.3%
Current Liabilities	$383K-74.2%	$215K-88.2%	$1.5M+389.1%	$1.5M+35.8%	$1.5M+853.6%	$1.8M+2130.2%	$298K+139.2%	$1.1M+310.6%
Non-Current Liabilities	$54K-38.1%	$62K-34.0%	$71K-30.5%	$79K-27.8%	$87K-24.8%	$94K-22.9%	$102K-21.3%	$109K-19.7%
Total Equity	$4.7M-14.7%	$6.6M-7.6%	$4.9M-49.7%	$3.0M-62.8%	$5.6M-45.2%	$7.1M+9.6%	$9.8M+161.2%	$8.0M+164.0%
Retained Earnings	-$68.5M-12.7%	-$66.5M-16.7%	-$65.1M-19.9%	-$63.5M-23.1%	-$60.8M-23.1%	-$57.0M-19.7%	-$54.3M-15.6%	-$51.6M-12.7%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

LEXX Cash Flow Statement

LEXX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$7.4M	-$10.5M-110.7%	-$5.0M+15.7%	-$5.9M-20.5%	-$4.9M-22.3%	-$4.0M-52.3%	-$2.6M+12.9%	-$3.0M-19.4%	-$2.5M-62.9%	-$1.5M-133.9%	-$661K+56.0%	-$1.5M-191.0%	-$516K-260.7%	$321K+136.1%	$136K+23.8%	$110K
Depreciation & Amortization	N/A	$51K+20.7%	$42K-70.8%	$145K+41.5%	$103K-8.1%	$112K-6.5%	$120K+84.0%	$65K+1525.6%	$4K+69.5%	$2K+280.8%	$619	$0	N/A	N/A	$0-100.0%	$425
Stock-Based Compensation	N/A	$859K+74.6%	$492K+188.9%	$170K-77.4%	$753K+83.6%	$410K-64.0%	$1.1M+81.8%	$627K-75.9%	$2.6M+2202.0%	$113K-7.4%	$122K-52.3%	$256K+164.0%	$97K+355.9%	$21K+87.7%	$11K-93.7%	$180K
Capital Expenditures	$41K	$25K-42.7%	$43K+27.5%	$34K-31.4%	$49K	N/A	$0-100.0%	$646K	N/A	$0-100.0%	$3K	$0	N/A	N/A	N/A	N/A
Free Cash Flow	-$7.5M	-$10.5M-109.4%	-$5.0M+15.4%	-$5.9M-20.0%	-$4.9M	N/A	-$2.6M+28.3%	-$3.7M	N/A	-$1.5M-132.8%	-$664K+55.8%	-$1.5M	N/A	N/A	N/A	N/A
Investing Cash Flow	-$244K	-$243K-28.9%	-$189K-11.2%	-$170K+6.1%	-$181K-193.2%	$194K+822.3%	-$27K+96.5%	-$769K-395.0%	-$155K-1502.2%	-$10K+51.8%	-$20K-102.9%	$685K+997.7%	-$76K-8.0%	-$71K+74.2%	-$274K+72.7%	-$1.0M
Financing Cash Flow	$6.5M	$6.0M-41.4%	$10.3M+548.9%	$1.6M+3664.4%	-$45K-100.3%	$13.4M+405.6%	$2.7M-20.4%	$3.3M+78.5%	$1.9M-53.3%	$4.0M+676.9%	$514K+37.8%	$373K-69.6%	$1.2M+436.5%	-$365K-227.1%	$288K-66.6%	$861K

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	-$1.6M+54.4%	-$2.2M-44.5%	-$984K+63.9%	-$2.6M-39.7%	-$3.6M-183.1%	-$1.5M-141.7%	-$2.7M-130.7%	-$1.9M-16.6%
Depreciation & Amortization	$14K-55.1%	$14K	$12K+37.5%	N/A	$31K+105.4%	N/A	$9K-69.7%	-$17K-124.4%
Stock-Based Compensation	N/A	N/A	$75K-24.7%	N/A	N/A	N/A	$99K+84.3%	N/A
Capital Expenditures	$0-100.0%	$41K+4081500.0%	$0-100.0%	$1-100.0%	-$1	$1	$25K	$43K
Free Cash Flow	-$1.6M+54.4%	-$2.2M-47.2%	-$984K+64.2%	-$2.6M-36.6%	-$3.6M-183.1%	-$1.5M-141.7%	-$2.8M-132.8%	-$1.9M-19.3%
Investing Cash Flow	-$27K-39.3%	-$54K-93.3%	-$5K+86.5%	-$158K-126.9%	-$19K+11.6%	-$28K+51.1%	-$38K+5.6%	-$70K-1.7%
Financing Cash Flow	$0-100.0%	$3.0M+25873.2%	$3.5M-20.1%	$0	$1.7M-66.5%	$12K-99.7%	$4.3M+138.8%	$0+100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

LEXX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LEXX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	99.6%+0.6pp	99.0%+12.9pp	86.1%+14.2pp	71.9%-3.9pp	75.7%+7.3pp	68.4%-21.3pp	89.7%-4.5pp	94.2%+40.9pp	53.3%+65.3pp	-12.0%	-103.3%	N/A	N/A	N/A	N/A
Operating Margin	-1683.0%	-1239.2%	-2888.5%	-2591.7%	-786.9%	N/A	N/A	N/A	N/A	-3136.8%	-13489.8%	N/A	N/A	N/A	N/A
Net Margin	-1686.0%	-1248.3%	-2946.4%	-2846.3%	-557.2%	-1297.6%	1841.8%	1523.2%	-3031.9%	-3136.8%	-13489.8%	N/A	N/A	N/A	N/A
Return on Equity	-398.1%-326.0pp	-72.1%+146.8pp	-218.9%-127.5pp	-91.5%-60.6pp	-30.8%+133.7pp	-164.5%-329.2pp	164.6%-111.8pp	276.4%+346.1pp	-69.7%+410.4pp	-480.1%-223.3pp	-256.8%-165.9pp	-90.8%	N/A	N/A	-20.2%
Return on Assets	-285.1%-219.7pp	-65.3%+150.8pp	-216.1%-123.3pp	-92.8%-62.4pp	-30.3%+114.1pp	-144.4%-297.7pp	153.3%-118.1pp	271.4%+338.9pp	-67.5%+158.0pp	-225.4%+53.2pp	-278.7%-219.5pp	-59.2%	N/A	N/A	-12.4%
Current Ratio	2.32-4.9x	7.18-0.9x	8.03-27.9x	35.96-45.2x	81.18+72.7x	8.53-1.3x	9.86-42.5x	52.34+22.1x	30.27	N/A	12.24+9.4x	2.80+2.7x	0.10-0.2x	0.280.0x	0.24
Debt-to-Equity	0.53+0.4x	0.150.0x	0.13+0.1x	0.030.0x	0.02-0.1x	0.14+0.1x	0.07+0.1x	0.020.0x	0.03-1.1x	1.13+1.1x	0.07-0.5x	0.53-0.2x	0.700.0x	0.73+0.1x	0.63
Asset Turnover	0.17+0.1x	0.050.0x	0.070.0x	0.030.0x	0.05-0.1x	0.110.0x	0.08-0.1x	0.18+0.2x	0.020.0x	0.07+0.1x	0.020.0x	0.00	N/A	N/A	N/A
FCF Margin	-1483.9%	-1077.4%	-2614.8%	-1929.8%	N/A	-831.9%	-1640.4%	N/A	-2429.2%	-1630.6%	-10209.7%	N/A	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Gross Margin	N/A	100.0%0.0pp	N/A	100.0%0.0pp	100.0%0.0pp	100.0%0.0pp	98.5%+1.7pp	100.0%0.0pp
Operating Margin	N/A	-7259.5%	N/A	-1545.2%	-2155.4%	-1581.0%	-1463.0%	-2622.7%
Net Margin	N/A	-7249.9%	N/A	-1549.3%	-2177.6%	-1559.3%	-1470.0%	-2600.9%
Return on Equity	-42.0%+26.2pp	-22.0%+16.0pp	-32.5%-4.8pp	-90.2%-63.0pp	-68.3%-50.6pp	-38.0%-28.0pp	-27.7%+3.8pp	-27.2%+13.5pp
Return on Assets	-41.6%+14.6pp	-22.4%+8.9pp	-26.4%+1.3pp	-64.6%-39.9pp	-56.2%-38.4pp	-31.3%-21.0pp	-27.6%+4.9pp	-24.6%+15.5pp
Current Ratio	10.60+6.7x	26.88+22.6x	3.68-26.0x	2.32-4.9x	3.90-54.4x	4.24-62.1x	29.64+8.0x	7.18-0.9x
Debt-to-Equity	0.09-0.2x	0.04-0.2x	0.31+0.3x	0.53+0.4x	0.28+0.3x	0.27+0.2x	0.040.0x	0.150.0x
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.040.0x	0.030.0x	0.020.0x	0.020.0x	0.010.0x
FCF Margin	N/A	-11023.4%	N/A	-1518.7%	-2059.7%	-860.9%	-1495.6%	-2303.2%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Lexaria Bioscience Corp LEXX	FY2025	$706K	-$11.9M	N/A	$8.5M	—
Curis CRIS	FY2025	$9.4M	-$7.6M	-80.3%	$2.9M	42/100
Aspire-lakewood Holdings Inc ASBP	FY2025	$6K	N/A	N/A	$12.1M	—
Promis Neuroscie PMN	FY2025	N/A	-$39.7M	N/A	$128.8M	—
Cingulate Inc CING	FY2025	N/A	-$22.4M	N/A	$75.8M	—
Neuraxis Inc NRXS	FY2025	$3.6M	-$7.8M	N/A	$72.0M	43/100

Where Lexaria Bioscience Corp Ranks

Frequently Asked Questions

What is Lexaria Bioscience Corp's annual revenue?

Lexaria Bioscience Corp (LEXX) reported $706K in total revenue for fiscal year 2025. This represents a 52.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lexaria Bioscience Corp's revenue growing?

Lexaria Bioscience Corp (LEXX) revenue grew by 52.0% year-over-year, from $464K to $706K in fiscal year 2025.

Is Lexaria Bioscience Corp profitable?

No, Lexaria Bioscience Corp (LEXX) reported a net income of -$11.9M in fiscal year 2025.

What is Lexaria Bioscience Corp's EBITDA?

Lexaria Bioscience Corp (LEXX) had EBITDA of -$11.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Lexaria Bioscience Corp's gross margin?

Lexaria Bioscience Corp (LEXX) had a gross margin of 99.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Lexaria Bioscience Corp's return on equity (ROE)?

Lexaria Bioscience Corp (LEXX) has a return on equity of -398.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lexaria Bioscience Corp's free cash flow?

Lexaria Bioscience Corp (LEXX) recorded an outflow of $10.5M in free cash flow during fiscal year 2025. This represents a -109.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lexaria Bioscience Corp's operating cash flow?

Lexaria Bioscience Corp (LEXX) recorded an outflow of $10.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Lexaria Bioscience Corp's total assets?

Lexaria Bioscience Corp (LEXX) had $4.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lexaria Bioscience Corp's capital expenditures?

Lexaria Bioscience Corp (LEXX) invested $25K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Lexaria Bioscience Corp spend on research and development?

Lexaria Bioscience Corp (LEXX) invested $8.2M in research and development during fiscal year 2025.

How many shares does Lexaria Bioscience Corp have outstanding?

Lexaria Bioscience Corp (LEXX) had 22M shares outstanding as of fiscal year 2025.

What is Lexaria Bioscience Corp's current ratio?

Lexaria Bioscience Corp (LEXX) had a current ratio of 2.32 as of fiscal year 2025, which is generally considered healthy.

What is Lexaria Bioscience Corp's debt-to-equity ratio?

Lexaria Bioscience Corp (LEXX) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lexaria Bioscience Corp's return on assets (ROA)?

Lexaria Bioscience Corp (LEXX) had a return on assets of -285.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lexaria Bioscience Corp's P/E ratio?

Lexaria Bioscience Corp (LEXX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to May 31, 2026). The market capitalization is $8.5M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Lexaria Bioscience Corp's price-to-sales ratio?

Lexaria Bioscience Corp (LEXX) trades at 44.0x sales, its market capitalization divided by revenue of $194K revenue, trailing 12 months to May 31, 2026. The market capitalization is $8.5M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Lexaria Bioscience Corp's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Lexaria Bioscience Corp (LEXX) held $2.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.5M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Lexaria Bioscience Corp's Altman Z-Score?

Lexaria Bioscience Corp (LEXX) has an Altman Z-Score of -26.68, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Lexaria Bioscience Corp's Piotroski F-Score?

Lexaria Bioscience Corp (LEXX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lexaria Bioscience Corp's earnings high quality?

Lexaria Bioscience Corp (LEXX) reported a net loss of $11.9M while operations used $10.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.